Japan· JP-3999463G3028
アダリムマブ（遺伝子組換え）［アダリムマブ後続３］
A medicinal product containing アダリムマブ（遺伝子組換え）［アダリムマブ後続３］, registered in Japan by 持田製薬, on the national reimbursement list.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- アダリムマブ（遺伝子組換え）［アダリムマブ後続３］
- Manufacturer
- 持田製薬
- Country
- Japan (JP)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
アダリムマブ（遺伝子組換え）［アダリムマブ後続３］ in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaAMGEVITAAmgen Europe B.V., Breda
- FinlandAMGEVITAAmgen Europe B.V.
- SwitzerlandAbrilada
- United StatesAdalimumabSandoz Inc
- BelgiumAmgevita 20 mgAmgen Europe
- SwedenAMGEVITA 20 mg Injektionsvätska, lösning i förfylld sprutaAmgen Europe B.V.
- IcelandAmgevitaAmgen Europe B.V.*
- NetherlandsAmgevita 20 mg, oplossing voor injectie in een voorgevulde spuitAmgen Europe B.V.
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Hukyndra, Humira
- Iceland · Amgevita, Amsparity
- Liechtenstein · Amsparity, Hefiya
- Norway · Amgevita, Amsparity
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e51ca575-5a2f-4efb-bd5e-4df8e88babbf GET /v1/drugs/e51ca575-5a2f-4efb-bd5e-4df8e88babbf?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "８０ｍｇ０．８ｍＬ１筒",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "3999463G3028",
"category": "注射薬",
"price_yen": 37546,
"generic_name": "アダリムマブ（遺伝子組換え）［アダリムマブ後続３］",
"product_name_jp": null,
"therapeutic_class": "3999",
"transitional_expiry": null
}See everything about アダリムマブ（遺伝子組換え）［アダリムマブ後続３］.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.